First Treatment Recommended for Rare Immunoglobulin-Related Autoimmune Disease
In September 2025, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended extending the indication of Uplizna® (inebilizumab) to include treatment of active Immunoglobulin G4-related disease (IgG4-RD) in adults. European Medicines Agency (EMA) IgG4-RD is a rare, chronic autoimmune disorder in which the body’s immune system attacks its own tissues, leading […]